Elite Pharmaceuticals (ELTP) filed an 8-K/A to amend its earlier report, solely to correct the date of its conference call. The company will host the call to discuss financial results for the second quarter of fiscal 2026, covering the period ended September 30, 2025.
The conference call is scheduled for Monday, November 17, 2025, at 11:30 AM EST. Dial-in: 1-800-346-7359 (domestic) or 1-973-528-0008 (international), conference number 98840. General questions may be emailed to dianne@elitepharma.com by 5:00 PM EST on November 13, 2025, and financial questions by 7:00 PM EST on November 14, 2025. The information is being furnished under Items 2.02, 7.01 and 9.01 and is not deemed filed under the Exchange Act.
Elite Pharmaceuticals (ELTP) announced FDA approval for its generic version of Requip XL (Ropinirole Extended-Release Tablets USP). The approval covers 2 mg, 4 mg, 6 mg, 8 mg, and 12 mg strengths used to treat symptoms of Parkinson’s disease. The product will be marketed and sold under the Elite Laboratories, Inc. label.
The company furnished a press release with these details as Exhibit 99.1. Information in this item and the press release is provided under Regulation FD and is not deemed filed under the Exchange Act.
Elite Pharmaceuticals (ELTP) announced it will host a conference call to discuss its second quarter fiscal 2026 results for the period ended September 30, 2025. The call is scheduled for November 14, 2025, at 11:30 AM EST.
Participants can dial 1-800-346-7359 (domestic) or 1-973-528-0008 (international) and use conference number 98840. Questions may be emailed to dianne@elitepharma.com; general questions are due by 5:00 PM EST on November 13, 2025, and financial questions by 7:00 PM EST on November 14, 2025.
Elite Pharmaceuticals (ELTP) filed a Form 4 disclosing that EVP Operations Douglas Plassche sold common stock. On 10/02/2025, he executed a sale (code S) of 800,000 shares at a price of $0.624 per share. Following the transaction, he beneficially owns 3,500,000 shares, held directly.
The filing identifies the reporting person as an officer (EVP Operations) and indicates the ownership form as direct. No derivative securities transactions were reported in Table II.